Compare PPSI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPSI | MDXH |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.2M | 41.1M |
| IPO Year | 2008 | 2021 |
| Metric | PPSI | MDXH |
|---|---|---|
| Price | $3.88 | $0.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 178.6K | ★ 758.2K |
| Earning Date | 04-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,627,000.00 | N/A |
| Revenue This Year | $2.71 | $30.78 |
| Revenue Next Year | $22.42 | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.75 | N/A |
| 52 Week Low | $2.35 | $0.45 |
| 52 Week High | $6.29 | $5.33 |
| Indicator | PPSI | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 43.42 | 18.95 |
| Support Level | $3.86 | N/A |
| Resistance Level | $4.35 | $3.79 |
| Average True Range (ATR) | 0.33 | 0.05 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 17.00 | 11.12 |
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets. The Company launched two new product platforms namely, PRYMUS, a new, mobile on-site power system concentrating on customers with requirements of 1-10 megawatts of mobile power and PowerCore, a residential and small commercial based primary generator system integrating a DC fast charger into one solution.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.